"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1995 | 2 | 4 | 6 |
| 1997 | 1 | 0 | 1 |
| 1998 | 5 | 1 | 6 |
| 1999 | 2 | 1 | 3 |
| 2000 | 3 | 1 | 4 |
| 2001 | 4 | 2 | 6 |
| 2002 | 3 | 2 | 5 |
| 2003 | 6 | 2 | 8 |
| 2004 | 9 | 2 | 11 |
| 2005 | 5 | 2 | 7 |
| 2006 | 5 | 3 | 8 |
| 2007 | 10 | 2 | 12 |
| 2008 | 6 | 1 | 7 |
| 2009 | 6 | 3 | 9 |
| 2010 | 8 | 3 | 11 |
| 2011 | 3 | 3 | 6 |
| 2012 | 7 | 2 | 9 |
| 2013 | 13 | 1 | 14 |
| 2014 | 6 | 2 | 8 |
| 2015 | 5 | 0 | 5 |
| 2016 | 5 | 8 | 13 |
| 2017 | 2 | 4 | 6 |
| 2018 | 6 | 3 | 9 |
| 2019 | 5 | 1 | 6 |
| 2020 | 3 | 1 | 4 |
| 2021 | 6 | 4 | 10 |
| 2022 | 5 | 0 | 5 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma. Blood Adv. 2023 07 11; 7(13):2983-2993.
-
Can Risk Stratification Tools Be Utilized to Safely Discharge Low-Risk Febrile Neutropenic Patients from the Emergency Department? J Emerg Med. 2023 Jan; 64(1):111-118.
-
Melphalan flufenamide for relapsed/refractory multiple myeloma. Drugs Today (Barc). 2022 Aug; 58(8):407-423.
-
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 05 13; 28(10):2020-2029.
-
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. Clin Cancer Res. 2022 04 14; 28(8):1672-1679.
-
Venetoclax ramp-up with concurrent voriconazole in a patient with chronic lymphocytic leukemia. J Oncol Pharm Pract. 2022 Dec; 28(8):1898-1901.
-
KIT Exon 9-Mutated Gastrointestinal Stromal Tumours: Biology and Treatment. Chemotherapy. 2022; 67(2):81-90.
-
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. J Clin Oncol. 2021 10 01; 39(28):3128-3139.
-
Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening. Cancer Discov. 2021 10; 11(10):2544-2563.
-
Gastrointestinal leiomyosarcoma demonstrate a predilection for distant recurrence and poor response to systemic treatments. Eur J Surg Oncol. 2021 10; 47(10):2595-2601.